Kymera Therapeutics (KYMR) Stock Forecast & Price Target

Kymera Therapeutics is attractive because its lead STAT6 degrader KT-621 has already shown biologic-like efficacy with >90% target degradation and a clean safety profile, while the 98% OLE rollover in atopic dermatitis suggests sustained patient interest and potential tolerability. Its second major asset, KT-579, cleared management’s 90% degradation bar and produced strong ex-vivo TLR pathway inhibition, which meaningfully de-risks the planned lupus study and supports a first-in-class autoimmune platform. The company also benefits from a broad pipeline, including KT-485 with SNY and a new program expected next year, while cash runway into 2029 and DCF-based positive outlooks reinforce the investment case.

Kymera Therapeutics is viewed cautiously because its investment case still hinges on unproven clinical data, with the key 3Q26 readout for the phase II STAT6 asset still pending and the company lacking any approved products or revenues. While IRF5 HV data support the lupus program, the stock already reflects elevated optimism at a $13B fully-diluted market cap, leaving limited room for disappointment if KT-621 fails to deliver biologics-like efficacy versus dupi and lebri. Added to that are meaningful risks from a novel degrader modality, possible safety issues in longer studies, competitive pressure, and the need to finance ongoing R&D without commercial cash flow.